OTCMKTS:LPHM Lee Pharmaceuticals (LPHM) Stock Price, News & Analysis $0.01 +0.00 (+7.69%) As of 06/5/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Lee Pharmaceuticals Stock (OTCMKTS:LPHM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Lee Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0120▼$0.014050-Day Range$0.00▼$0.3652-Week Range$0.01▼$0.40Volume116,952 shsAverage Volume54,707 shsMarket Capitalization$492.27 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Lee Pharmaceuticals, Inc., through its subsidiary, RONN Motor Group, Inc., focuses on the design and development, manufacture, marketing, and sale of all-electric, hydrogen-fuel cell, and zero-emission new energy vehicles (NEVs) in the United States, China, and internationally. It intends to offer hydrogen fuel cell NEVs, including sports cars, sedans, SUVs, trucks, and buses. The company was founded in 2013 and is based in Scottsdale, Arizona. Read More Receive LPHM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lee Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LPHM Stock News HeadlinesGan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist BofanglutideApril 9, 2026 | prnewswire.comGan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2March 31, 2026 | prnewswire.com“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen winner of the AI race' may soon split into three separate companies in an event known as a starburst. Investors who buy shares before the announcement could automatically receive equal shares in each spinoff. In GE's 2021 starburst, one position became three, unlocking $184 billion for shareholders. Chaikin believes this AI starburst could be significantly larger.June 8 at 1:00 AM | Chaikin Analytics (Ad)Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight ManagementNovember 27, 2025 | prnewswire.comGan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific SessionsJune 21, 2025 | prnewswire.comGan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or ObesityMarch 10, 2025 | prnewswire.comGan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two WeeksNovember 12, 2024 | prnewswire.comLongboard Pharmaceuticals (LBPH) Receives a Hold from Truist FinancialNovember 11, 2024 | markets.businessinsider.comSee More Headlines LPHM Stock Analysis - Frequently Asked Questions How have LPHM shares performed this year? Lee Pharmaceuticals' stock was trading at $0.36 at the start of the year. Since then, LPHM stock has decreased by 96.1% and is now trading at $0.0140. How do I buy shares of Lee Pharmaceuticals? Shares of LPHM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today6/08/2026Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorConsumer Staples Industry Toilet preparations Sub-IndustryBusiness Services Current SymbolOTCMKTS:LPHM Previous SymbolOTCMKTS:LPHM CIK58411 Webwww.leepharmaceuticals.com Phone(307) 278-1360Fax626-442-6994Employees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares35,162,000Free Float15,823,000Market Cap$492.27 thousand OptionableNot Optionable Beta669.91 Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:LPHM) was last updated on 6/8/2026 by MarketBeat.com Staff. From Our PartnersThe "hidden" half of the SpaceX IPOMost investors are focused on the SpaceX IPO - but the bigger opportunity may lie elsewhere. On Feb. 2, Elon M...Weiss Ratings | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | Sponsored“The unseen winner of the AI race” is not SpaceXMarc Chaikin - the analyst who called Nvidia before its historic run - says a tech firm labeled 'the unseen wi...Chaikin Analytics | SponsoredWhy I'm NOT Buying the SpaceX IPO (And What I'm Buying Instead)The media's calling it "the biggest IPO in Wall Street history." But I'm not buying it. Institutions got into ...Decentralized Masters | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredSpaceX billions need somewhere to go — this is itThe SpaceX IPO is projected to raise $75 billion in a single day... When that happens, the insiders who cashed...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lee Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lee Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
